vimarsana.com

Page 3 - Vaccine Administration Under Emergency Use Authorization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioNTech SE: Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U S Government for Donation to Poorest Nations

U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022Doses to be donated to approximately 100 low- and lower middle-income countries including

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U S Government for Donation

U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX FacilityEffort is part of the companies’ recent pledge of two billi.

Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of Pfizer-BioNTech COVID-19 Vaccine

Date Time Share Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of Pfizer-BioNTech COVID-19 Vaccine NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.

Pfizer and BioNTech to Supply the European Union With up to 1 8 Billion Additional Doses of COMIRNATY®

Pfizer and BioNTech to Supply the European Union With up to 1 8 Billion Additional Doses of COMIRNATY®
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Pfizer Inc : Pfizer and BioNTech to Supply the European Union With up to 1 8 Billion Additional Doses of COMIRNATY

Pfizer Inc.: Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY Additional dose deliveries beginning December 2021 through 2023 Pfizer and BioNTech have now committed a total of up to 2.4 billion doses of COMIRNATY to the EC since the beginning of the pandemic Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY , the companies COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005450/en/

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.